<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231022059813N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-14</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of risperidone and aripiprazole in the treatment of the acute phase of mania</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of risperidone and aripiprazole as a clinical trial in treating the acute phase of mania in patients with bipolar disorders</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73366</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, volunteers will be assigned to two groups by simple randomization method. The drugs used are delivered to the patients in a similar form and appearance. Coding of the intervention groups is done by one of the experts of the psychiatric department of the hospital, and the research group will be unaware of the coding until the end of the research.
In order to randomize people into two groups, calculator.net online software generated 76 random numbers between the numbers 1 and 76, and the numbers generated in the range {1-38} were assigned to the control group and the numbers generated in the range {39-76} were assigned to the intervention group, which is shown in the following sequence:
BBBABBBBBBAAAABBAABBAABBBAAAABABAAABBBABAAABBBBBBBAAAAABBABABAAABBBBABAAAAAAA, Blinding description: The used drugs are delivered to the mentioned patients in a similar form and appearance. Coding of the intervention groups will be done by one of the experts of the psychiatric department of the hospital, and the research group (participant and clinical caregiver and researcher and outcome evaluator) will be unaware of the coding until the end of the research.</study_design>
      <phase>3</phase>
      <hc_freetext>Comparison of the effect of risperidone and aripiprazole as a clinical trial in treating the acute phase of mania in patients with bipolar disorders.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Resperidone 2 mg tablet of Biopharma company once a night and sodium valproate tablet of Raha company 500 mg a night orally for two weeks. Intervention 2: Intervention group 2: Aripiprazole 10 mg tablet of Sobhan Shabi company and sodium valproate tablet of Raha company 500 mg once orally during two weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Mustafa Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nasser Khosro Street, Shahid Timuri Street, Yadgar Imam Som Alley</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6816947174</zip>
        <telephone>+98 66 3320 5264</telephone>
        <email>dr.mousavi1988@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mustafa Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nasser Khosro Street, Shahid Timuri Street, Yadgar Imam Som Alley</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6816947174</zip>
        <telephone>+98 66 3320 5264</telephone>
        <email>dr.mousavi1988@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient consent to participate in the study
Suffering from the acute phase of mania of bipolar disorder, which must be confirmed by a psychiatrist</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of sensitivity and allergy to aripiprazole and risperidone
Physical illness</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Resperidone 2 mg tablet of Biopharma company once a night and sodium valproate tablet of Raha company 500 mg a night orally for two weeks</i_keyword>
      <i_keyword>Intervention group 2: Aripiprazole 10 mg tablet of Sobhan Shabi company and sodium valproate tablet of Raha company 500 mg once orally during two weeks</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Comparison of risperidone and aripiprazole in the treatment of manic phase of bipolar disorder. Timepoint: The beginning of the study and 7 and 14 days after the beginning of the mania phase. Method of measurement: Jung's Mania Rating Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in increasing energy. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in elevated mood. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in increasing libido. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in sleep disorder. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in irritability. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in talkative speech. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in thought disorder. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in Thought content disorder. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in aggression. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in appearance beauty. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
      <sec_outcome>Comparison of risperidone and aripiprazole in disease insight. Timepoint: At the beginning of the study and 7, 14 days after starting to take the drug. Method of measurement: Yang's Mania Rating Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-18</approval_date>
        <contact_name>Ethics Committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>Nasser Khosrokh Street, Shahid Timuri Street, Yadgar Imam Som Alley Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
